• About
  • Archive
  • Privacy & Policy
  • Contact
Dana Blankenhorn
  • Home
  • About Dana
  • Posts
  • Contact Dana
  • Archive
  • A-clue.com
No Result
View All Result
  • Home
  • About Dana
  • Posts
  • Contact Dana
  • Archive
  • A-clue.com
No Result
View All Result
Dana Blankenhorn
No Result
View All Result
Home business strategy

Can Open Source Save Big Pharma?

by Dana Blankenhorn
June 22, 2011
in business strategy, Health, innovation, intellectual property, investment, open source
3
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Detrol logo Big pharmaceutical companies like Johnson & Johnson, Pfizer and Abbott Labs  have a problem software companies can relate to.

The costs of drug discovery, and drug trials, have grown exponentially, resulting in a smaller pipeline of new drugs and massive consolidation throughout the industry.

For software, open source provided a partial answer. By pooling basic technology through groups like the Eclipse Foundation and Apache, software companies have been able to reduce costs while retaining the power to innovate and sell innovations.

While health IT has used the open source process, both publicly (through the VA's redevelopment of its VistA platform) and privately (through groups like Open Health Tools) drug delivery itself remains a proprietary affair.

Now Pfizer is taking the first baby steps away from an all-proprietary formula by sharing the design of its first all-electronic drug trial, for the bladder control drug Detrol.

A number of companies are providing technology that lets Pfizer recruit trial participants online and have those people manage their own therapy. Myrtus is working on the front-end. Exco inTouch provides the mobile e-diary equipment. Perceptive Informatics is providing the back-end processing. The University of California is providing third-party validation.


Open health tools logo

The result, it's hoped, will be a lower-cost process for trials, which are one of the biggest cost sinks in drug research. Some, like Tomasz Sablinski of Celtic Therapeutics, want to expand the approach into full-fledged open source drug research  but we are a long way from that.

A shared IT approach to trials will not, by itself, re-start the new drug pipeline, but it could be the first step toward a shared infrastructure approach that might.

Tags: Detroldrug studiesdrugsopen sourceopen source medicineopen source studiesPfizer
Previous Post

Mark Kelly for Senate

Next Post

Biting the Long Tail

Dana Blankenhorn

Dana Blankenhorn

Dana Blankenhorn began his career as a financial journalist in 1978, began covering technology in 1982, and the Internet in 1985. He started one of the first Internet daily newsletters, the Interactive Age Daily, in 1994. He recently retired from InvestorPlace and lives in Atlanta, GA, preparing for his next great adventure. He's a graduate of Rice University (1977) and Northwestern's Medill School of Journalism (MSJ 1978). He's a native of Massapequa, NY.

Next Post
Biting the Long Tail

Biting the Long Tail

Comments 3

  1. exposed skin Care amazon says:
    12 years ago

    exposed skin Care amazon

    Dana Blankenhorn: Can Open Source Save Big Pharma?

    Reply
  2. from this source says:
    12 years ago

    from this source

    Dana Blankenhorn: Can Open Source Save Big Pharma?

    Reply
  3. patchwork fabric says:
    12 years ago

    patchwork fabric

    Dana Blankenhorn: Can Open Source Save Big Pharma?

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Post

The Ride Back Home

The Ride Back Home

May 17, 2025
Bicycle Diplomacy Changing the World

Bicycle Diplomacy Changing the World

May 16, 2025
The E-Transport Revolution Rolls On

Change the Subject, Atlanta

May 14, 2025
The Coming Labor War

The Insanity of Wealth

May 7, 2025
Subscribe to our mailing list to receives daily updates direct to your inbox!


Archives

Categories

Recent Comments

  • Dana Blankenhorn on The Death of Video
  • danablank on The Problem of the Moment (Is Not the Problem of the Moment)
  • cipit88 on The Problem of the Moment (Is Not the Problem of the Moment)
  • danablank on What I Learned on my European Vacation
  • danablank on Boomer Roomers

I'm Dana Blankenhorn. I have covered the Internet as a reporter since 1983. I've been a professional business reporter since 1978, and a writer all my life.

  • Italian Trulli

Browse by Category

Newsletter


Powered by FeedBlitz
  • About
  • Archive
  • Privacy & Policy
  • Contact

© 2023 Dana Blankenhorn - All Rights Reserved

No Result
View All Result
  • Home
  • About Dana
  • Posts
  • Contact Dana
  • Archive
  • A-clue.com

© 2023 Dana Blankenhorn - All Rights Reserved